162 results
Page 5 of 9
8-K
EX-99.1
b6025k9vu
4 Nov 19
Karyopharm Reports Third Quarter 2019 Financial Results and Highlights Recent Company Progress
7:07am
8-K
EX-99.1
s7rryo
6 Aug 19
Results of Operations and Financial Condition
7:13am
8-K
EX-99.1
f9yqu13umb6 dbny
3 Jul 19
Karyopharm Announces FDA Approval of XPOVIOTM(selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
1:10pm
424B5
1qwfw2ndmzezxa tzv
10 May 19
Prospectus supplement for primary offering
4:16pm
8-K
EX-99.1
evyn3b
9 May 19
Results of Operations and Financial Condition
7:10am
DEFA14A
mfo3448t q3a
19 Apr 19
Additional proxy soliciting materials
4:08pm
PRE 14A
l794c0ivj
2 Apr 19
Preliminary proxy
4:29pm
8-K
EX-99.1
u7fu71j ocb
28 Feb 19
Karyopharm Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
7:22am
8-K
EX-10.1
eau8m50y8j1yzveb7
18 Jan 19
Departure of Directors or Certain Officers
4:06pm
8-K
EX-10.2
pem303
18 Jan 19
Departure of Directors or Certain Officers
4:06pm
8-K
EX-99.1
hxb8y 9ok
7 Jan 19
Regulation FD Disclosure
8:26am
8-K
EX-99.1
7mz1joi 1s
8 Nov 18
Karyopharm Reports Third Quarter 2018 Financial Results and Highlights Recent Company Progress
7:08am
424B5
h7y1xos2mx k4
17 Aug 18
Prospectus supplement for primary offering
4:05pm
8-K
EX-10.1
4qkxe
17 Aug 18
Entry into a Material Definitive Agreement
4:01pm